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2Abstract
Autotaxin, encoded by the Enpp2 gene, generates lysophosphatidic acid (LPA)
extracellularly, eliciting various cellular responses through specific LPA receptors.
Previous studies have revealed that Enpp2-/- mice die at E9.5 owing to angiogenic defects
in the yolk sac. Moreover, Enpp2-/- embryos show growth retardation, allantois
malformation, no axial turning, and head cavity formation. We have also demonstrated
that lysosome biogenesis is impaired in yolk sac visceral endoderm cells of Enpp2-/-
embryos as a result of the downregulation of the Rho-ROCK (Rho-associated coiled-coil
containing protein kinase)-LIM kinase pathway. In this study, we examine what signaling
defect(s) is responsible for head cavity formation and yolk sac angiogenic defects. By
using a whole embryo culture system, we show that 10 µM Ki16425, an antagonist for the
LPA receptors, induces head cavity formation and yolk sac angiogenic defects in wild-
type embryos. Moreover, 1 µM Ki16425 induces both phenotypes in Enpp2 heterozygous
embryos at significantly higher incidence than in wild-type embryos, suggesting an
interaction between autotaxin and LPA receptor signaling. Furthermore, we show that
inhibition of the Rho-ROCK pathway induces head cavity formation, whereas multiple
pathways are involved in yolk sac angiogenic defects. These results reveal the signal
transduction defects that underlie the abnormalities in Enpp2-/- embryos.
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3Introduction
Autotaxin, also known as ENPP2 (ectonucleotide
pyrophosphatase/phosphodiesterase 2), is an exoenzyme having lysophospholipase D
activity that generates lysophosphatidic acid (LPA) in the extracellular space [1, 2]. It
elicits a wide variety of biological responses such as cell proliferation, migration, survival,
and neurite retraction through activating specific G protein-coupled receptors (LPA1-6) [3-
7]. LPA receptors are coupled to several intracellular pathways, including Rho/ROCK
(Rho-associated coiled-coil containing protein kinase), phosphatidylinositol 3-kinase
(PI3K), mitogen activated protein kinase (MAPK), and phospholipase C (PLC) pathways
through distinct G proteins [3-7]. In addition to LPA production, autotaxin was shown to
generate sphingosine 1-phosphate (S1P) in vitro [8] although the in vivo roles of autotaxin
in S1P production remain to be established.
Several studies have shown that Enpp2-/- mice die at E9.5 owing to angiogenic
defects in the yolk sac [9-13]. Enpp2-/- embryos also show pleiotropic defects, such as
growth retardation, allantois malformation, neural tube defects, no axial turning, and head
cavity formation [9-13]. In addition, adult Enpp2-heterozygous mice show half-normal
levels of lysophospholipase D activity and LPA, but normal levels of S1P, in plasma [9,
10], suggesting that autotaxin is a major LPA-producing enzyme in vivo.
In a previous study, we demonstrated that lysosome biogenesis was impaired in
yolk sac visceral endoderm (VE) cells of Enpp2-/- embryos [12]. By using a whole embryo
culture system combined with specific inhibitors, we showed that the control of actin
turnover dynamics through the Rho-ROCK-LIM kinase pathway was required to form
large lysosomes in VE cells [12]. However, it remains unknown what signaling defect(s) is
responsible for other phenotypes of Enpp2-/- embryos.
4Here, we show that inhibition of the LPA receptors induces head cavity formation
and yolk sac angiogenic defects in a whole embryo culture. In addition, we show that
blockade of the Rho/ROCK pathway results in the head cavity formation, whereas
multiple pathways are involved in the angiogenic defects. These findings demonstrate the
specific role of the LPA receptor-Rho-ROCK pathway in head cavity formation in Enpp2-
/- embryos.
Materials and methods
Animal Experiments. All the experiments using animals were approved by the
Animal Care and Use Committee of the University of Tsukuba and performed under its
guidelines. Noon of the day on which a vaginal plug was observed was taken as
embryonic day 0.5 (E0.5). Enpp2-deficient mice were generated and genotyped as
described previously [12]. Timed-pregnant ICR mice (CLEA Japan, Tokyo, Japan; Japan
SLC, Hamamatsu, Japan) were used for the pharmacological experiments.
Histology, immunohistochemistry, and LacZ staining. Embryos were fixed with
4% paraformaldehyde/PBS at 4°C overnight. For histological examination, 4-µm-thick
paraffin sections were stained with hematoxylin and eosin. For PECAM-1 immunostaining,
10-µm-thick cryostat sections were treated with 0.3% H2O2 in PBS, blocked with PBS
supplemented with 1% heat-inactivated normal goat serum and 0.1% Tween 20, and then
incubated with anti-PECAM-1 (1:400; BD Biosciences Pharmingen, San Diego, CA,
USA) at 4°C overnight. After washing, the slides were incubated with biotin-SP-
conjugated anti-rat IgG (1:500; Jackson ImmunoResearch, West Grove, PA, USA),
followed by the chromogenic staining using a VECTASTAIN Elite ABC kit and DAB
substrate kit (Vector Laboratories, Burlingame, CA, USA). For SMA immunostaining, the
slides were incubated with HRP-conjugated anti-SMA (DAKO, Glostrup, Denmark),
5followed by fluorescent signal detection using a TSA kit #12 (Invitrogen, Carlsbad, CA,
USA). LacZ staining was carried out by incubating the fixed embryos in PBS containing 5
mM K4Fe(CN) 6, 5 mM K3Fe(CN) 6, 1 mg/ml X-gal, 2 mM MgCl2, 0.02% Nonidet P40,
and 0.01% Na deoxycholate.
RT-PCR. Reverse transcription and PCR were performed as previously described
[12]. Quantitative PCR was carried out using a LightCycler and LightCycler FastStart
DNA Master SYBR Green I reagent (Roche Diagnostics, Basel, Switzerland). Expression
levels were normalized by β-actin expression. Primer sequences and PCR conditions are
available upon request.
Ex vivo whole embryo culture. Whole embryo culture was performed as previously
described [12, 14]. Briefly, embryos were dissected at E7.5 and cultured in 100% rat
serum (Charles River, Yokohama, Japan) supplemented with 2 mg/ml glucose in a culture
bottle placed in a rotation drum culture system (Ikemoto Rika, Tokyo, Japan) at 37°C
under 5% O2, 5% CO2 and 90% N2 for the initial 24h, followed by 20% O2, 5% CO2 and
75% N2 for the next 24 h. The reagents used were Ki16425 (1-10 µM; Sigma-Aldrich, St.
Louis, MO, USA), VPC 23019 (1-10 µM; Avanti Polar Lipids, Alabaster, AL, USA),
Clostridiusm botulinum exoenzyme C3 (20 µg/ml; Calbiochem, Darmstadt, Germany),
H1152 (0.1 µM; Calbiochem), pertussis toxin (0.5 µg/ml; Calbiochem), LY294002 (10
µM; Sigma-Aldrich), PD98059 (10 µM; Calbiochem), U-73122 (10 µM; Sigma-Aldrich),
and cytochalasin B (0.03-0.3 µM; Calbiochem).
Results
Enpp2 -/- embryos have abnormal cavities in the head and trunk regions
We re-examined Enpp2 -/- embryos and found that abnormalities appeared at earlier
stages than previously reported [9-13]; at E7.5, a small cavity had formed between the
6embryonic endoderm and mesoderm (Figures 1A-B). At E8.5, a large cavity was found in
the head mesenchyme in all Enpp2 -/- embryos (Figures 1C-E) as reported previously [9-
13]. At E9.5, most Enpp2-/- embryos showed arrested development (Figure 1F). The head
cavities were confined to one side in most Enpp2-/- embryos from E7.5 to E8.5, whereas
they were present bilaterally at E9.5. Some Enpp2-/- embryos had cavities in the trunk
region at E9.5 (Figure 1G).
Enpp2 -/- embryos have angiogenic defects of the yolk sac
Enpp2-/- embryos show angiogenic defects in the yolk sac [9-13]. In Enpp2-/-
embryos, endothelial cells, stained with the endothelial cell marker PECAM-1/CD31, had
formed a nearly normally honeycomb-like vascular plexus at E8.5 (Figures 1J, L, N),
whereas branched vitelline vessels were not formed at E9.5 (Figure 1R, T, V). Thus, de
novo differentiation of endothelial cells (“vasculogenesis” [15]) appeared to be normal,
whereas maturation and remodeling of blood vessels (“angiogenesis” [15]) were impaired
in Enpp2-/- embryos. Smooth muscle cells, revealed by smooth muscle actin
immunostaining, appeared to form normally in Enpp2-/- embryos (Figure 1O-P, W-X).
We next examined the expression of cell-type specific markers for the yolk sac:
vascular endothelial zinc finger (Vezf1), vascular endothelial growth factor receptor 2
(Flk1/Kdr), and endoglin (Eng) for endothelial cells; smooth muscle actin (Acta2) and
SM22α (Tagln) for pericytes/smooth muscle cells; alpha fetoprotein (Afp), quaking (Qk),
claudin7 (Cldn7), and hepatocyte nuclear factor 4α (Hnf4a) for VE cells. Semi-
quantitative RT-PCR showed that expression of these markers was comparable between
the control and Enpp2-/- embryos at E8.5 (Figure 1Y, data not shown). In addition,
angiogenesis-promoting factors, such as vascular endothelial growth factor A (Vegfa),
transforming growth factor β1 (TGFβ1; Tgfb1), and angiopoietin-1 (Ang1), were
7expressed normally in Enpp2-/- yolk sacs and embryos proper at E8.5. In contrast, at E9.5,
Vegfa, Tgfb1, and Ang1 were upregulated in Enpp2-/- embryos proper (about 6.8-, 2.4-, and
1.8-fold, respectively, as assessed by quantitative PCR), suggesting that Enpp2-/- embryos
became hypoxic because of vascular insufficiency (Figure 1Y). Furthermore, expression
of an apoptosis-associated gene, Gadd153, was upregulated and many TUNEL-positive
cells were detected in the E9.5 embryos proper (Figure 1Y, data not shown).
Taken together, these findings indicate that the head cavity was formed well before
the deterioration of Enpp2-/- embryos, which started at about E9.5 when angiogenic defects
were evident. Therefore, in the following experiments, we focused on two obvious and
robust phenotypes at relatively healthy stages, head cavity formation at E8.5 and yolk sac
angiogenic defects at E9.5, and examined the signal transduction defects responsible for
these phenotypes.
A whole embryo culture system mimics in vivo development faithfully
To examine the downstream pathways of autotaxin, we used an ex vivo whole
embryo culture [12, 16]. This is a well-established system that is useful for studying
normal development and developmental toxicity in vitro [16]. When E7.5 wild-type
embryos were cultured for 1 or 2 days, they showed a normal appearance comparable to
those of in-utero-grown E8.5 and E9.5 embryos, respectively (Figure 2A, E, I). In addition,
when blood vessels were visualized using whole-mount lacZ staining of the embryos
carrying E. coli lacZ in the Flk1 gene (Flk1lacZ mice, a kind gift of J. Rossant) [17], normal
branched vitelline vessels were observed in wild-type embryos after 2 days of culture
(Figure 2M). In contrast, when Enpp2-/- embryos were cultured for 1 day, most of them
had head cavities (Figures 2F, Q) that were indistinguishable from those of E8.5 Enpp2-/-
embryos grown in utero. Moreover, all Enpp2-/- embryos showed yolk sac angiogenic
8defects (Figures 2J, N, R) that were indistinguishable from those seen in the E9.5 Enpp2-/-
embryos grown in utero. These results indicate that a whole embryo culture system
mimics in vivo development of wild-type and Enpp2-/- embryos faithfully, thus making it
suitable for testing whether blockade of the downstream signal transduction pathways
induces the defects observed in Enpp2-/- embryos. In the following experiments, we used
inhibitors at the concentrations determined in our previous study [12].
Blockade of LPA receptors leads to head cavity formation
We first tested inhibitors of LPA and S1P receptors. When wild-type mouse
embryos were cultured with Ki16425, an LPA1/LPA3 antagonist [18], for 1 day, the head
cavity was formed in a dose-dependent manner; 10 µM Ki16425 induced the cavity
formation to the same extent as that observed in non-treated Enpp2-/- embryos. (Figure 2G,
Q). In contrast, 10 µM VPC23019, an S1P1/S1P3 antagonist [19], did not induce head
cavity formation (Figure 2H, Q). These findings indicate that LPA receptors are the major
mediators downstream of autotaxin.
We further examined the functional linkages between autotaxin and LPA receptors
in another way. Because Enpp2 heterozygous mice show half-normal levels of LPA [9,
10], thus having reduced levels of downstream signaling, they should be more sensitive to
the inhibitors than are wild-type mice. We thus tested whether a subthreshold level of the
inhibitors can induce abnormalities in the heterozygous mice. When Enpp2+/+ embryos
were cultured with 1 µM of Ki16425, head cavity formation was induced at low incidence
(n = 2/17), whereas the same concentration of Ki16425 induced head cavity formation at
significantly higher incidence (n = 12/23) in Enpp2+/- embryos (P < 0.01, chi-square test
for independence) (Figure 2S), suggesting an interaction between autotaxin and LPA
receptor signaling. In contrast, treatment with 1 µM VPC23019 led to a slight increase of
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= 0/10), but the difference was not significant (P > 0.05) (Figure 2S). These findings
demonstrate that the defects in LPA receptors, but not in S1P receptors, underlie head
cavity formation in Enpp2-/- embryos.
Blockade of LPA receptors leads to yolk sac angiogenic defects
In contrast to head cavity formation, either 10 µM Ki16425 or 10 µM VPC23019
induced yolk sac angiogenic defects (Figure 2O-P, R), suggesting that both LPA and S1P
receptors are required for normal angiogenesis. These findings are compatible with those
of previous reports that autotaxin promotes angiogenesis in cultured endothelial cells or in
a murine in vivo angiogenesis model [20] and that both LPA and S1P have angiogenic
activity in vitro and in vivo [21-23].
We wondered whether both pathways function downstream of autotaxin. To
address this question, we again tested whether Enpp2 heterozygous mice were more
sensitive to the inhibitors. A low concentration (1 µM) of Ki16425 induced a significantly
higher incidence of angiogenic defects in Enpp2+/- embryos than in Enpp2+/+ embryos
(Enpp2+/+, n = 1/8; Enpp2+/-, n = 5/8; P < 0.01, chi-square test for independence) (Figure
2T), suggesting an interaction between autotaxin and LPA receptors in angiogenesis. In
contrast, treatment with 1 µM VPC23019 resulted in a slight increase of angiogenic
defects in Enpp2+/- embryos (n = 5/12) compared with those in Enpp2+/+ embryos (n = 1/6),
but the difference was not significant (P > 0.05) (Figure 2T). These data suggest that S1P
receptors have little, if any, significance in autotaxin-mediated angiogenesis in the yolk
sac. Taken together, these findings indicate that the defects in LPA receptor signaling are
responsible for head cavity formation and yolk sac angiogenic defects in Enpp2-/- embryos.
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Blockade of the Rho/ROCK signaling pathway leads to head cavity formation
The major downstream pathways of LPA receptors are G12/13-RhoA, Gi-PI3K-Rac,
Gi-MAPK, and Gq-PLC [3-7]. We thus examined which signaling pathway(s) is associated
with the phenotypes of Enpp2-/- embryos. Treatment of embryos with a Rho inhibitor,
Clostridium C3 exoenzyme (20 µg/ml), or a ROCK inhibitor, H1152 (0.1 µM), resulted in
head cavity formation, whereas treatment with a Gi inhibitor, pertussis toxin (0.5 µg/ml); a
PI3K inhibitor, LY294002 (10 µM); a MAPK inhibitor, PD98059 (10 µM); or a PLC
inhibitor, U-73122 (10 µM), showed no significant effects on head cavity formation
(Figure 3A-F, S). These findings suggest that the Rho/ROCK pathway is specifically
involved in head cavity formation.
Blockade of multiple signaling pathways leads to yolk sac angiogenic defects
In contrast to head cavity formation, all the inhibitors used in this study (C3
exoenzyme, H1152, pertussis toxin, LY294002, PD98059, and U-73122) induced
angiogenic defects (Figure 3M-R, T). These findings indicate that Rho, ROCK, Gi, PI3K,
MAPK, and PLC are required for some aspects of angiogenesis in the yolk sac.
Blockade of actin polymerization leads to head cavity and yolk sac angiogenic defects
Because LPA induces Rho-mediated cytoskeletal rearrangement, we wondered whether
direct perturbation of the actin cytoskeleton caused the abnormalities observed in Enpp2-/-
embryos. We addressed this question by treating mouse embryos with cytochalasin B, a
cell-permeable inhibitor of actin polymerization. When mouse embryos were cultured with
cytochalasin B, it induced head cavity formation and angiogenic defects in a dose-
dependent manner (Figure 4). This result suggests that actin depolymerization leads to
head cavity formation and angiogenesis in the yolk sac.
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Discussion
In this study, we showed that blockade of LPA receptors led to head cavity
formation and angiogenic defects in mouse embryos. Moreover, we demonstrated that the
Rho-ROCK pathway was specifically associated with the head cavity formation, whereas
multiple intracellular signaling pathways were involved in angiogenesis. These latter
results are compatible with the findings of previous reports that gene disruption of the
components of G12 (Gna12)/G13 (Gna13), MAPK (Mekk3), PLC (Plcg1), or PI3K
(Pik3ca) led to angiogenic defects in the yolk sac [24-28].
Head cavity formation is a very characteristic phenotype in Enpp2-/- embryos. To
the best of our knowledge, there has been no report of knockout mice that have cavities in
the head mesenchyme, while only a teratogen, trypan blue, was reported to induce similar
head cavities in rat embryos in vitro and in vivo [29]. Trypan blue inhibited lysosome
functions in yolk sac VE cells [30], which play a critical role in the maternofetal exchange
of nutrients prior to the formation of the chorioallantoic placenta [31, 32]. In addition, a
previous study suggested that osmotic imbalance as a result of the transport defects of VE
cells resulted in head cavity formation [29]. When cavities were formed in Enpp2-/-
embryos, the cells surrounding the cavities appeared to be deformed as if squeezed by
pressure, suggesting that the cavity was formed as the result of abnormal fluid
accumulation. Given that Enpp2-/- embryos have lysosomal defects in VE cells [12], and
that the inhibitors of the Rho-ROCK pathway specifically lead to the defects in lysosome
biogenesis [12] and head cavity formation (this study), osmotic imbalance caused by the
VE cell dysfunction may induce head cavity formation in Enpp2-/-embryos. Further studies
are necessary to elucidate the link between cavity formation and abnormalities in VE cells.
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Figure Legends
Figure 1. Head cavity formation and yolk sac angiogenic defects in Enpp2-/- embryos. (A-
H) Gross appearance and histological sections. Lateral views (A, C, F-H) and frontal
views (D). WT indicates Enpp2+/+ or Enpp2+/- embryos; -/- indicates Enpp2-/- embryos. At
E7.5, blisters were formed between the embryonic endoderm and mesoderm in Enpp2-/-
embryos (arrow, A; asterisk, B). At E8.5-E9.5, large cavities were formed in the head
mesenchyme (hm) (arrows, C-D, F-G; asterisk, E). At E9.5, the Enpp2-/- embryos became
much smaller than the controls (F). Some mutant embryos showed cavities in the trunk
region (arrowheads) (G). At E9.5, large vitelline vessels were formed in the control (black
arrow, H) but not in the Enpp2-/- yolk sac. Abbreviations: am, amnion; ch, chorion; ne,
neuroepithelium; ys, yolk sac. Scale bars: 480 µm (A, C, D), 280 µm (B), 250 µm (E), and
1.3 mm (F-H). (I-X) Immunostaining of PECAM-1 and smooth muscle actin (SMA). At
E8.5, the primary vascular plexus had formed nearly normally in the Enpp2-/- yolk sac,
although the honeycomb-like patterns were slightly rough and the capillaries slightly
dilated (J, L, N). At E9.5, branched vascular networks were seen in the controls (Q), but
not in the Enpp2-/- yolk sacs (R). Abnormally dilated spaces were formed in the Enpp2-/-
embryos (asterisks, T, V, X). Abbreviations: ep, embryo proper; epc, epiplacental cone; ve,
visceral endoderm. Scale bars: 600 µm (I-J), 220 µm (K-L, S-T), 40 µm (M-N, U-V), 30
µm (O-P, W-X), and 450 µm (Q-R). (Y) RT-PCR of angiogenesis-related genes. RT(-)
indicates a control reaction without reverse transcriptase.
Figure 2. Blockade of LPA receptors results in head cavity formation and yolk sac
angiogenic defects. (A-L) Gross appearance of the yolk sac and embryo after they were
cultured for 1 or 2 days in vitro (DIV). (M-P) Vitelline vessels revealed by whole-mount
lacZ staining. Enpp2-/- embryos showed both head cavity formation (arrow, F) and yolk
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sac angiogenic defects (J, N). Arrowheads in (J) indicate the mesodermal cell layers
separated from the yolk sac. Mouse embryos cultured with 10 µM Ki16425 (an
LPA1/LPA3 antagonist) showed head cavity formation (arrow, G), whereas those cultured
with 10 µM Ki16425 or 10 µM VPC23019 (an S1P1/S1P3 antagonist) showed angiogenic
defects (K-L, O-P). Scale bar: 600 µm (A-H), 800 µm (I-L), and 250 µm (M-P). (Q-T)
Effects of Ki16425 (Ki) and VPC23019 (VPC) on cultured embryos. Data show the
percentages of embryos with head cavity formation or yolk sac angiogenic defects. A low
concentration (1 µM) of Ki16425, which had a marginal effect on wild-type (+/+)
embryos, induced both head cavity formation and angiogenic defects in Enpp2
heterozygous (+/-) embryos (S-T). The number of embryos examined is shown in each
column. The asterisks over the columns represent significant differences (* P < 0.05, **P
< 0.01, and ***P < 0.001) as compared with the wild-type (WT) or control embryos (chi-
square test for independence).
Figure 3. Blockade of the Rho/ROCK pathway results in head cavity formation and yolk
sac angiogenic defects. (A-L) Gross appearance of the yolk sac and embryo after they
were cultured for 1 or 2 days in vitro (DIV). (M-R) Vitelline vessels revealed by whole-
mount lacZ staining. Mouse embryos cultured in the presence of a Rho inhibitor (20 µg/ml
C3 exoenzyme; A, G, M) or a ROCK inhibitor (0.1 µM H1152; B, H, N) showed both
head cavity formation and yolk sac angiogenic defects. Mouse embryos cultured with the
inhibitors of Gi (0.5 µg/ml pertussis toxin; PTX), phosphatidylinositol 3-kinase (10 µM
LY294002), MAP kinase (10 µM PD98059), or phospholipase C (10 µM U-73122)
showed angiogenic defects. Scale bar: 60 µm (A-F), 80 µm (G-L), and 25 µm (M-P). (S-
T) Percentages of embryos with head cavity formation and yolk sac angiogenic defects
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after inhibitor treatment. The number of embryos examined is shown in each column. The
asterisks over the columns represent significant differences (*P < 0.05, **P < 0.01, and
***P < 0.001) as compared with the control embryos (chi-square test for independence).
Figure 4. Blockade of actin polymerization results in head cavity formation and yolk sac
angiogenic defects. (A-D) Gross appearance of the yolk sac and embryo after they were
cultured for 1 or 2 days in vitro (DIV). Lateral view (B) and frontal views (A, C-D). (E)
Vitelline vessels revealed by whole-mount lacZ staining. Mouse embryos cultured with an
actin polymerization inhibitor, cytochalasin B (0.3 µM), showed head cavity formation
(arrow, C) and angiogenic defects (E). Scale bar: 600 µm (A-B), 400 µm (C), 800 µm (D),
and 250 µm (E). (F-G) Percentages of embryos with head cavity formation and/or yolk sac
angiogenic defects after cytochalasin B treatment. The number of embryos examined is
shown in each column. The asterisks over the columns represent significant differences
(*P < 0.05 and **P < 0.01) as compared with the control embryos (chi-square test for
independence).




